Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-17 4:07 pm Purchase | 2025-12-31 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Vestal Point Capital, LP | 3,830,000 6.500% | 3,830,000 (New Position) | Filing History |
| 2025-11-14 5:32 pm Sale | 2025-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Venrock Healthcare Capital Partners III L.P. | 3,226,331 5.400% | -800,000 (-19.87%) | Filing History |
| 2025-11-05 11:35 am Purchase | 2025-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | FMR LLC | 7,870,219 13.300% | 1,967,954 (+33.34%) | Filing History |
| 2025-08-14 5:06 pm Purchase | 2025-06-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Commodore Capital LP | 6,022,957 9.900% | 1,922,957 (+46.90%) | Filing History |
| 2025-08-14 4:03 pm Purchase | 2025-06-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Fairmount Funds Management LLC | 3,711,444 6.300% | 508,646 (+15.88%) | Filing History |
| 2025-08-14 08:01 am Purchase | 2025-06-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Polar Capital Holdings Plc | 2,536,881 5.170% | 147,213 (+6.16%) | Filing History |
| 2025-07-17 7:54 pm Purchase | 2025-06-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | BlackRock Inc. BLK | 2,941,395 5.100% | 4,753 (+0.16%) | Filing History |
| 2025-06-17 5:30 pm Unchanged | 2025-06-16 | 13D | ENLIVEN THERAPEUTICS INC ELVN | ORBIMED ADVISORS LLC | 7,918,163 13.400% | 0 (Unchanged) | Filing History |
| 2025-02-14 3:45 pm Unchanged | 2024-12-31 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Fairmount Funds Management LLC | 3,202,798 6.600% | 0 (Unchanged) | Filing History |
| 2025-02-14 09:17 am Sale | 2024-12-31 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Polar Capital Holdings Plc | 2,389,668 4.890% | -298,129 (-11.09%) | Filing History |
| 2024-11-14 5:48 pm Purchase | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Venrock Healthcare Capital Partners III L.P. | 4,026,331 8.500% | 1,071,429 (+36.26%) | Filing History |
| 2024-11-14 5:46 pm Sale | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | RA CAPITAL MANAGEMENT L.P. | 1,061,233 2.200% | -1,061,232 (-50.00%) | Filing History |
| 2024-11-14 4:24 pm Purchase | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | CITADEL ADVISORS LLC | 1,734,094 3.700% | 1,307,237 (+306.25%) | Filing History |
| 2024-11-14 4:15 pm Purchase | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Fairmount Funds Management LLC | 3,202,798 6.800% | 1,071,429 (+50.27%) | Filing History |
| 2024-11-14 4:05 pm Purchase | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Commodore Capital LP | 4,100,000 8.700% | 1,198,184 (+41.29%) | Filing History |
| 2024-11-13 5:55 pm Purchase | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Polar Capital Holdings Plc | 2,687,797 5.690% | 2,687,797 (New Position) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | BlackRock Inc. BLK | 2,936,642 6.200% | 0 (Unchanged) | Filing History |
| 2024-10-24 2:02 pm Purchase | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | BlackRock Inc. BLK | 2,936,642 6.200% | 2,936,642 (New Position) | Filing History |
| 2024-07-29 6:12 pm Sale | 2024-07-25 | 13D | ENLIVEN THERAPEUTICS INC ELVN | 5AM Ventures VI L.P. | 2,304,332 4.900% | -531,543 (-18.74%) | Filing History |
| 2024-05-20 4:55 pm Sale | 2024-05-16 | 13D | ENLIVEN THERAPEUTICS INC ELVN | ORBIMED ADVISORS LLC | 7,918,163 16.800% | -1,033,300 (-11.54%) | Filing History |